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Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver pathologyfrom simple steatosis alone, through necroinflammatory disorder referred to as nonalcoholic steatohepatitis (NASH), to cirrhosis and liver cancer. Because of the high prevalence and the potential mortality, NAFLD/NASH has emerged as a serious public concern and therefore therapeutic strategies need to be established. Recent animal studies and clinical trials have demonstrated several pharmacological treatments as potential therapeutic targets, which include insulin sensitizers (e.g., thiazolidinediones, metoformin), lipid lowering agents (e.g., statins, fibrates), antioxidants, angiotensin (Ang) II type I receptor (AT1R) blockers (ARBs), etc [1] [2] [3] [4] [5] [6] [7] . Among these therapeutic options, ARBs are initially expected to suppress the development of hepatic fibrosis in NASH. Hepatic stellate cell (HSC), which is a major fibrogenic cell type in the liver and also contributes to hepatic inflammation through induction of cytokines, expresses AT1R, and blockade of Ang II signaling markedly attenuates hepatic inflammation and fibrosis in experimental models of chronic liver fibrosis [8, 9] . In addition, clinical report has demonstrated that treatment with losartan improved hepatic necroinflammation and fibrosis in NASH patients [10] .
In addition to anti-fibrotic/inflammatory effect, emerging data have suggested that ARBs improve glucose and lipid metabolism. In a large clinical trial, losartan substantially lowered the risk Nabeshima et al, Role of AT1 receptor in hepatic steatosis 6 for type 2 diabetes compared with other antihypertensive therapies [11] . Animal study using obese Zucker rat has also demonstrated that high dose of irbesartan improved insulin sensitivity [12] . More recently, it has been shown that telmisartan, unlike other ARBs improved the development of hepatic steatosis in animal models [7, 13, 14] . These metabolic effects of ARBs might be explained in part by the in vitro study, in which a distinct subtype of ARBs induced transcriptional activities of peroxisome proliferator-activated receptor (PPAR) γ, independent of their AT1R blocking actions [15, 16] . However, it is noteworthy that PPAR γ-activating potency by ARBs appears rather modest as determined by transcription reporter assays, with median effective concentration (EC 50 ) of telmisartan, the most potent PPARγ activator among ARBs, 5.02 µmol/L compared to 0.2 µmol/L of pioglitazone, a full agonist of PPARγ [15, 16] . Interestingly, treatment with olmesartan, which has no impact on PPARγ activation, has been proved to attenuate the development of hepatic steatosis, suggesting the possibility that the blockade of AT1R itself might contribute to hepatic lipid homeostasis [17] . To further investigate the direct role for AT1R in hepatic steatosis, we applied to different approaches: 1) animal model of steatohepatitis using mice lacking AT1aR (AT1a -/-), which is the only Ang II receptor subtype expressed in rodent liver, and 2) in vitro cellular steatosis model in which gene silencing by RNA interference targeting AT1R was performed [18] . Our data demonstrated reduced lipid accumulation in the absence of AT1R with significant induction of PPARα. Apart from PPARγ modulating action of ARBs, these
Experimental Procedures

Animal
AT1a -/-mice were provided by Mitsubishi Tanabe Pharma (Osaka, Japan) and C57BL/6 mice were obtained from Charles River Laboratories (Yokohama, Japan) [19] . Both strains of the mice have the same genetic background. The mice were housed in a standard 12 h light/dark cycle facility, and fed either standard chow diet or methionine-choline deficient (MCD) diet (Oriental Yeast Co., Tokyo, Japan) for 8 weeks with free access to drinking water. Male mice at 6-8 weeks of age were used in this study, and all animal procedures were done according to the guideline of Institute of Laboratory Animal Science, Hiroshima University.
Histological examination
Liver samples were fixed in 4 % formaldehyde solution, embedded in paraffin, and cut into 5
µm-thick sections. Staining for hematoxylin and eosin (H-E) or Azan-Mallory was carried out with standard techniques.
Analytical techniques
Serum triglyceride (TG) concentration was determined enzymatically using a Triglyceride Nabeshima et al, Role of AT1 receptor in hepatic steatosis 9 E-test (Wako Chemicals, Osaka, Japan). To quantify hepatic TG content, hepatic lipid was extracted as previously described by Bligh and Dyer and subjected to the same procedure as serum assay followed by the standardization of protein concentrations [20] . Hepatic thiobarbituric acid-reactive substances (TBARS) levels were quantified using an OXI-TEK TBARS Assay Kit (Zeprometrix Corporation, New York) with protein standardization. Serum TBARS levels were assayed using the same kit.
Beta-hydroxybutyrate was assayed using an assay kit (BioVision, Mountain View, CA). The activities of serum transaminases were determined enzymatically. and β-hydroxybutyrate levels in the media.
Nile Red assay
The lipid content in cultured cells was quantified fluorometrically using Nile Red, a vital lipophilic dye as previously described [22] . Briefly, cell monolayers were washed twice with 
Quantitative real-time PCR.
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Germany). cDNA was synthesized from 1µg of total RNA with GeneAmp Gold RNA PCR Core Kit (Applied Biosystems, Foster City, CA).
To quantify AT1R mRNA expression in human heart and kidney, PCR Ready First Strand cDNA (BioChain, Hayward, CA) was utilized. Specific primers except AT1R from PrimerBank, a public resource for PCR primers (http://pga.mgh.harvard.edu/primerbank/, ID: 14043066) were designed using Primer3 (http://fokker.wi.mit.edu/primer3/input.htm) with nucleotide sequences from GenBank TM as listed in Table 1 . Real-time PCR was carried out with Lightcycler 1.5 system using Lightcycler FastStart DNA Master plus SYBR Green I (Roche Applied Science). The relative expression levels were calculated with the formula 2 -∆Ct , where ∆Ct is the difference in threshold cycle (Ct) values between target gene and ribosomal protein S18 as a control.
Western blot analysis for AT1R
Fifty microgram of protein prepared from HepG2 cells using RIPA buffer supplemented with protease inhibitors (Roche Diagnostics), as well as Total Protein-Human Adult Normal Tissues (Biochain, Hayward, CA) were fractionated by SDS-PAGE and subjected to Western blot analysis using rabbit polyclonal antibodies against human AT1R (N-10) (Santa Cruz Biotechnology, Santa Cruz, CA).
The blots were visualized by enhanced chemiluminescence.
Statistical analysis
The data are expressed as the means±S.E. The statistical analysis was performed using Student's t test, and differences were considered statistically significant for a two-tailed p<0.05.
Results
Mice lacking AT1R are resistant to steatohepatitis
MCD diet has been reported to cause steatohepatitis which represents most of histological feature of human NASH [24, 25] . As shown in Figure 1A , histological analysis of the livers demonstrated that MCD diet for 8 weeks resulted in apparent steatosis with inflammatory cell infiltration mainly in portal area in wild-type (WT) mice. However, in contrast to WT mice, AT1a -/-mice displayed no significant changes in the liver ( Figure 1A , right panel). Azan-Mallory staining of the liver from WT mice revealed mild pericellular fibrosis, which was absent in AT1a -/-mice ( Figure 1A , lower panels).
In accordance with these histological observations, hepatic TG content increased by 3-fold in WT and remained no significant 1.5-fold increase in AT1a β-hydroxybutyrate, an end product of hepatic fatty acid oxidation. Figure 1D demonstrates 3-fold increase in serum β-hydroxybutyrate in AT1a -/-mice compared to WT mice following MCD diet. This might be a potential explanation for reduced hepatic lipid accumulation in AT1a -/-mice.
Lack of AT1R ameliorates liver injury
As shown in Figure 2 , there were no differences in aspartate aminotransferase (AST) and alanine aminotrasferase (ALT) levels between WT and AT1a -/-mice when fed chow diet. MCD diet caused significant increase in AST and ALT levels in WT mice, whereas there was no significant increase of these liver enzymes in AT1a -/-mice.
Influence of AT1R expression on oxidative stress
Since lipid peroxidation product plays an important role as a "2 nd . hit" in the pathogenesis of NASH, we next examined serum and hepatic levels of TBARS [26] . 
AT1R blockade reduces lipid accumulation in hepatocellular in vitro model
To examine whether AT1R expression in HepG2 was functional, we utilized in vitro model of steatosis in which HepG2 cells were treated with FFAs mixture with or without 10 µM of telmisartan.
As shown in Figure 5A Compared to the treatment of telmisartan, the influence of AT1R knockdown appeared modest. This might be because siRNA suppression of AT1R was not sufficient to elicit complete inhibition of the AT1R signaling pathway. In connection with the observed ketogenesis in AT1a -/-mice, we examined β-hydroxybutyrate levels in the culture media. Under the condition of 200 µM of FFAs overload, the treatment of telmisartan as well as AT1R knockdown significantly increased β-hydroxybutyrate levels ( Figure 5C ).
AT1R knockdown induces PPARa and its target genes
The observation that hepatic PPARα expression was up-regulated in AT1a -/-mice suggests the possible link between AT1R signaling and PPARα expression. In this setting, our working hypothesis is that AT1R down-regulation may in turn influence the hepatocellular expressions of PPARα and its target genes. As shown in Figure 6A , transient AT1R silencing by siRNA resulted in significant up-regulation of PPARα by 41%. In addition, PPARα target genes, acyl-CoA synthetase 1 (ACSL1) and apolipoprotein B (Apo B) 100 were also induced by 27 and 21 %, respectively. These data exclude the possibility that PPARα up-regulation in AT1a -/-mice might be resulted from chronic adaptation to the absence of AT1R. To exclude the possible contribution of the other PPAR isoforms in hepatocellular steatosis, the expression of PPARγ and PPARβ(δ) were assessed by real-time PCR, which resulted in no significant changes following AT1R depletion ( Figure 5B ).
Discussion
The present study indicates a major role for AT1R in hepatic steatosis by providing a precise of ARBs on hepatic steatosis is still controversial [7, 14, 17, [28] [29] [30] . These conflicting findings might be explained by differences in selective PPARγ modulating properties of ARBs [15, 16] , or attributed to differences in the dose and length of ARBs supplementation as well as potential differences in the mechanisms of steatosis in the different experimental models. Our data reinforces the theory that blockade of AT1R, unrelated to pharmacological properties of ARBs, ameliorates the development of hepatic steatosis.
The pathophysiology of NASH remains poorly understood, but is often described as "two-hit process" consisting of hepatic TG accumulation (the 1 st . step) and development of oxidative stress and proinflammatory cytokines (the 2 nd . step), which leads to hepatocyte injury, inflammation, and fibrosis Nabeshima et al, Role of AT1 receptor in hepatic steatosis 19 [26] . Previous reports have demonstrated that pharmacological blockade or gene deletion of renin-angiotensin system (RAS) significantly attenuates hepatic fibrosis in experimental animal models [31, 32] . Moreover, Ang II, the effecter peptide for AT1R, has been reported to stimulates an array of fibrogenic actions in activated HSCs through the mediation of reactive oxygen species [33] . More recent data has revealed that angiotensin converting enzyme (ACE) deficient (ACE -/-) mice which exhibit reduced levels of Ang II by 70 % in plasma and by 85-97 % in tissues [34] showed pronounced increase in hepatic gene expression related to lipolysis and fatty acid oxidation, suggesting close link between RAS and hepatic lipid metabolism [35] . Taken together with our finding of the anti-steatotic effect, the blockade of AT1R appears to contribute to wide range of steps and phases in the pathogenesis of NASH.
The up-regulation of PPARα in the liver of AT1a -/-mice is intriguing because PPARα plays a central role in hepatic lipid homeostasis. It is well known that many of the genes encoding enzymes involved in the mitochondrial and peroxisomal fatty acid β-oxidation pathways are regulated by PPARα.
To exclude the possibility that adaptation to persistent AT1R absence may induce PPARα expression in mice, we performed in vitro siRNA experiments, which confirmed induction of PPARα and its target genes by transient AT1R knockdown. In support of these observations, previous experiments have demonstrated telmisartan-mediated induction of PPARα [36] . Whereas induction of PPARα was observed in AT1a -/-mice, the present study lacks the direct evidence that suppressive effect of AT1R blockade on hepatic steatosis is mediated by PPARα.
In this connection, we examined β-hydroxybutyrate levels since it is documented that PPARα activation leads to stimulation of ketogenesis [37, 38] . This yielded marked increase in serum β-hydroxybutyrate in AT1a -/-mice. In A potential limitation of the present study is the use of MCD dietary animal model. Although this model develops steatohepatitis morphologically similar to human NASH with increase in oxidative stress and has been widely used for the study of NASH, absence of insulin resistance has been reported [24, 25, 39, 40] . Since insulin resistance is considered to be pivotal in the development of NASH, this model might not entirely reflect the natural course and the etiological background of human NASH [41, 42] . Some other potential dietary models include ad libitum feeding of the high fat diet, which develops obesity and insulin resistance but not noticeable steatohepatitis [43] . Additionally, intragastric overfeeding of high fat diet induces NASH pathology, but some of the biological changes observed in Nabeshima et al, Role of AT1 receptor in hepatic steatosis 21 the liver did not mimic human NASH [44] . Altogether, the study of pathophysiological process of NASH is limited by the lack of suitable experimental animal models [45] . Interestingly, the effect of olmesartan has been investigated in a genetically diabetic rat fed MCD diet [30] . In contrast to our findings, olmesartan reduced hepatic steatosis only in diabetic but not in control rats. In the present study, MCD diet caused increase in hepatic TG content associated with decrease in serum TG level, suggesting that impaired TG secretion from liver might contribute to hepatic steatosis. These changes were blunted in the absence of AT1R, implying improvement of TG secretion in AT1a -/-mice. This might be in part explained by the observation of in vitro experiment that AT1 knockdown induced Apo B which is requisite for the formation of very low density lipoprotein (VLDL).
In the present study, human hepatoma cell line HepG2 instead of rodent primary hepatocytes was utilized for in vitro model of cellular steatosis. This was based on the previous report that human primary hepatocytes and HepG2 cells reached similar levels of intracellular lipid accumulation close to that determined in hepatocytes from human steatosis liver [23] . In addition, the observed up-regulation of hepatic PPARα in AT1a -/-mice led to the speculation that PPARα might play a role in the anti-steatotic effect of AT1 blockade. Because hepatic expression of PPARα and the sensitivity to it notably differ among species [46] , human-derived cell line was applied.
In conclusion, mice lacking AT1R are resistant to the development of hepatic steatosis with 
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